In Acute Leukemia With Heavily Pretreated Patients, Menin Inhibitor Yields 63 Percent ORR.

Published Date: 15 Dec 2023

FDA is now reviewing the experimental medication revumenib for KMT2A-rearranged disease.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Kate Middleton and Remission: Oncologists Weigh In

2.

Advanced imaging, targeted therapy help men with prostate cancer safely defer surgery and radiation therapy

3.

Will a Mindfulness-Based Treatment for Depression Increase Recovery Rates?

4.

Novel topical fluorescent imaging technique rapidly and safely detects basal cell carcinoma

5.

Some low-grade prostate cancers carry higher risks than biopsy suggests


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot